Serum Krebs von den Lungen-6: promising biomarker to differentiate CPFE from IPF Serum KL-6: Discriminate CPFE from IPF
Main Article Content
Keywords
Combined pulmonary fibrosis emphysema, Idiopathic pulmonary fibrosis, Krebs von den Lungen-6, Surfactant protein-A, Surfactant protein-D, Pulmonary function tests, Echocardiography
Abstract
Background
Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phenotype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pulmonary fibrosis) patients.
Methods
Patients diagnosed with ‘CPFE’ and ‘IPF’ were consecutively included in 6 months as two groups. The patients with connective tissue diseases are excluded.
Results
In this study, 47 patients (41 males, 6 females) with CPFE (n = 21) and IPF (n = 26) with a mean age of 70.12 ± 8.75 were evaluated. CPFE patients were older, had more intense smoking history, had lower DLCO/VA, lower FVC, and worse six-minute walking distance than the IPF group (p=0.005, p=0.027, p=0.02, p<0.001, p=0.001, respectively). Serum KL-6 levels were higher in CPFE group compared to IPF group [264.70 U/ml (228.90-786) vs 233.60 (101.8-425.4), p<0.001]. Serum KL-6 levels of 245.4 U/ml and higher have 81% sensitivity and 73% specificity for the discrimination of CPFE from IPF.
Conclusions
Our study has shown that serum KL-6 level is a promising biomarker to differentiate CPFE from IPF. In CPFE cases respiratory and functional parameters are worse than those of pure fibrosis cases.
References
2. Mejía M, Carrillo G, Rojas-Serrano J, Estrada A, Suárez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009; doi: 10.1378/chest.08-2306.
3. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han M K, Gross B H, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J. 2011; doi:10.1183/09031936.00114010.
4. Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similarmortality to pulmonary fibrosis without emphysema. Lung. 2010; doi: 10.1007/s00408-010-9251-6.
5. Xu L, Bian W, Gu XH, Shen C. Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis. COPD. 2017; doi: 10.1080/15412555.2017.1278753.
6. Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012 Jan;141(1):222-231. doi: 10.1378/chest.11-1062.
7. Cottin V, Cordier JF. The syndrome of combined pulmonary fibrosis and emphysema. Chest. 2009; doi: 10.1378/chest.09-0538.
8. Kishaba T, Shimaoka Y, Fukuyama H, Yoshida K, Tanaka M, Yamashiro S, et al. A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema. BMJ Open. 2012; doi: 10.1136/bmjopen-2012-000988.
9. Cottin V. The impact of emphysema in pulmonary fibrosis. Eur Respir Rev. 2013; doi: 10.1183/09059180.00000813.
10. Niewoehner DE, Hoidal JR. Lung fibrosis and emphysema: divergent responses to a common injury? Science. 1982 Jul 23;217(4557):359-60.
11. Lang MR, Fiaux GW, Gillooly M, Stewart JA, Hulmes DJ, Lamb D. Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs. Thorax. 1994 Apr;49(4):319-26.
12. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lungdiseases. Am J Respir Crit Care Med. 2002 Feb 1;165(3):378-81.
13. Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K. The radiological patterns of interstitial change at an early phase: over a 4-yearfollow-up. Respir Med. 2010; doi: 10.1016/j.rmed.2010.05.014.
14. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96:68–73.
15. Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1680-4.
16. Kuroki Y, Tsutahara S, Shijubo N, Takahashi H, Shiratori M, Hattori A, et al. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis. 1993 Mar;147(3):723-9.
17. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1860-6.
18. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonaryfibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1109-14.
19. Chiba S, Ohta H, Abe K, Hisata S, Ohkouchi S, Hoshikawa Y, et al. The Diagnostic Value of the Interstitial Biomarkers KL-6 and SP-D for the Degree of Fibrosis in Combined Pulmonary Fibrosis and Emphysema. Pulm Med. 2012; doi: 10.1155/2012/492960.
20. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993 Sep;148(3):637-42.
21. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995 Aug;108(2):311-5.
22. Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology.2006 Mar;11(2):164-8.
23. Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012 Mar;50(1):3-13.
24. Samukawa T, Hamada T, Uto H, Yanagi M, Tsukuya G, Nosaki T, et al. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D. BMC Pulm Med. 2012; doi: 10.1186/1471-2466-12-55.
25. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; doi: 10.1164/rccm.2009-040GL.
26. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J 2005;26(1):153-161.
27. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005 Oct;26(4):720-35.
28. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J. 1993; doi: 10.1183/09041950.005s1693.
29. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC.
Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:41-52.
30. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014; doi: 10.1183/09031936.00150314.
31. Kocyigit H, Aydemir O, Fisek G, Olmez N, Memis A. Validity and reliability of Turkish version of Short form 36: A study of a patients with romatoid disorder. Journal of Drug and Therapy (in Turkish) 1999, 12:102-106.
32. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: testproperties and minimal clinically important difference. Am J Respir Crit Care Med. 2011; doi: 10.1164/rccm.201105-0840OC.
33. Akagi T, Matsumoto T, Harada T, Tanaka M, Kuraki T, Fujita M, et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med. 2009; doi: 10.1016/j.rmed.2009.02.001.
34. Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J. 2017; doi: 10.1183/13993003.00379-2017.
35. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis:a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003 Apr 1;167(7):962-9.
36. Mura M, Zompatori M, Pacilli AM, Fasano L, Schiavina M, Fabbri M. The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Respir Care. 2006 Mar;51(3):257-65.
37. Witt S, Krauss E, Barbero MAN, Müller V, Bonniaud P, Vancheri C, et al. Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respir Res. 2019; doi: 10.1186/s12931-019-1010-5.
38. Tomioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal study. Intern Med. 2007;46(18):1533-42.
39. Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005 Jul;60(7):588-94.
40. Weiner P, Novitzky T, Weiner D, Beckerman M. Chronic obstructive pulmonary disorder (COPD) patients with the syndrome of combined pulmonary fibrosis and emphysema, compared to patients with emphysema alone. Harefuah. 2013 May;152(5):294-8, 308, 307.
41. Cottin V, Le Pavec J, Prévot G, Mal H, Humbert M, Simonneau G, et al; GERM"O"P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010; doi: 10.1183/09031936.00038709.
42. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007 Sep;132(3):998-1006.
43. Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med. 1999 Feb;159(2):646-78.
44. Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathicpulmonary fibrosis. Respir Med. 2014; doi: 10.1016/j.rmed.2014.04.009.
45. Ishii H, Kushima H, Kinoshita Y, Fujita M, Watanabe K. The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression. Clin Respir J. 2018; doi: 10.1111/crj.12946.
46. Kokuho N, Ishii T, Kamio K, Hayashi H, Kurahara M, Hattori K, et al. Diagnostic Values For Club Cell Secretory Protein (CC16) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema. COPD. 2015; doi: 10.3109/15412555.2014.948994.
47. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitiallung diseases. J Intern Med. 2006 Nov;260(5):429-34.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
